DEFA14A: Edgewise Therapeutics Corrects Share Count and Director Class in Proxy Statement Supplement

Edgewise Therapeutics issues a supplement to its definitive proxy statement to correct the number of outstanding shares and the class of directors being elected at the annual meeting.

Summary

• Edgewise Therapeutics has filed a supplement to its definitive proxy statement.
• The supplement corrects the number of outstanding shares of common stock as of the record date for the Annual Meeting.
• The original proxy statement incorrectly stated the number of shares as 95,205,683.
• The corrected number of outstanding shares is 105,152,692.
• The supplement also corrects a reference to the class of directors being elected.
• The original proxy statement incorrectly referred to Class III directors.
• The corrected statement refers to the election of two Class I directors.
• All other information in the Proxy Statement remains unchanged.

Sentiment

Score: 7

Explanation: The document is a routine correction to a proxy statement, indicating a neutral sentiment. The correction of errors is a positive sign of due diligence.

Negatives

• The original proxy statement contained inaccuracies regarding the share count and director class.

Key Dates

Keywords

proxy statement, Edgewise Therapeutics, annual meeting, common stock, directors, shares outstanding, correction